Navigation Links
Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment
Date:11/3/2011

velopment for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS has submitted an NDA for avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely," "may," "plan," "potential," "predict," "opportunity," "should," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the response from the United States Food and Drug Administration, or FDA, to our resubmission of the New Drug Application, or NDA, for Qnexa for the treatment of obesity, including weight loss and maintenance of weight loss, recommended for obese patients (BMI >/= 30 kg/m2), or overweight patients (BMI >/= 27 kg/m2) with weight-related co-morbidities such as hypertension, type 2 diabetes, dyslipidemia, or central adiposity (abdominal obesity), with a contraindication that excludes the use of Qnexa by women of child-bearing potential; the timing and results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy; the reliability of the electronic medical claims healthcare databases used in the FORTRESS study; the FDA's interpretation of and agreement with the information VIVUS submitted relating to teratogenicity and cardiovascular safety; the FDA's interpretation of the data from our SEQUEL study (OB-305) and Sleep Apnea study (OB-204); that we may be required to conduct additional prospective studies or retr
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Multiple Presentations Featuring QNEXA® Data to be Presented at the European Congress on Obesity
2. QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities
3. Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits
4. Long-Term Data on QNEXA® to be Presented at The American College of Cardiology Annual Meeting
5. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
6. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
7. New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years
8. Isis Initiates Phase 1 Studies with Isis-GCGRRx and Isis-GCCRRx to Treat Type 2 Diabetes
9. Pharmasset Announces the Initiation of an Interferon-Free Phase 3 Program with PSI-7977 for HCV
10. Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling
11. Cytogel Pharma, LLC. Announces Presentation at the American Society of Anesthesiologists meeting in Chicago on October 18, 2011, Describing Results From its First Human Study, Part of the Phase I Program for Cyt-1010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... FRANCISCO , July 29, 2015  Nektar Therapeutics (Nasdaq: ... second quarter ended June 30, 2015 on Wednesday, August 5, ... Robin , president and chief executive officer, will host a ... Eastern Time (ET)/2:00 p.m. Pacific Time (PT). ... conference call can be accessed through a link that is ...
(Date:7/29/2015)... 29, 2015 Unilife Corporation (NASDAQ: ... and supplier of injectable drug delivery systems, today ... instant patch pumps for insulin. ... pump that does not require filling or assembly ... pre-assembled like an insulin pen, only three intuitive ...
(Date:7/29/2015)... 2015  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ... second quarter ended June 30, 2015. "We ... and Fanapt" said Mihael H. Polymeropoulos M.D., Vanda,s President ... cycle management of our products set the stage for ... Financial Highlights , Total net product sales ...
Breaking Medicine Technology:Nektar to Announce Financial Results for the Second Quarter 2015 on Wednesday, August 5, 2015, After Close of U.S.-Based Financial Markets 2Nektar to Announce Financial Results for the Second Quarter 2015 on Wednesday, August 5, 2015, After Close of U.S.-Based Financial Markets 3Unilife Introduces World's First Instant Patch Pump for Insulin 2Unilife Introduces World's First Instant Patch Pump for Insulin 3Unilife Introduces World's First Instant Patch Pump for Insulin 4Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 2Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 3Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 4Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 5Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 6Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 7Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 8Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 9Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 10Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 11Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 12Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 13Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 14
... 2011 Eli Lilly and Company (NYSE: ... signed agreements with private investors Care Capital and ... and privately-held biotechnology company. BioCritica, based in Central ... development and commercialization of Xigris® (drotrecogin alfa (activated)), ...
... ATLANTA, May 23, 2011 CardioMEMS, Inc ., ... is commercializing a proprietary wireless sensing and communication technology ... and CEO, Jay Yadav, M.D., was presented with a ... by the Atlanta Business Chronicle.  The award was conferred ...
Cached Medicine Technology:Lilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement 2Lilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement 3Lilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement 4Lilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement 5Lilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement 6Lilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement 7CardioMEMS Founder Dr. Jay Yadav Honored With Health-Care Heroes Award by the Atlanta Business Chronicle 2CardioMEMS Founder Dr. Jay Yadav Honored With Health-Care Heroes Award by the Atlanta Business Chronicle 3
(Date:7/29/2015)... ... July 30, 2015 , ... In ... BOC approved provider of online continuing education courses for Athletic Trainers , ... exclusive Andrews Research and Education Sports Medicine Series. , The new online continuing ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... If you’re ... as reported on June 3, 2015 by the Orange County Register , more ... fast-food chain Lee’s Sandwiches. While the article does not mention any reported illnesses that ...
(Date:7/29/2015)... ... , ... Sports fans young and old at the National Cherry Festival in ... Lions, joined by A Forever Recovery, a holistic treatment center for substance abuse located ... Bowl Offensive Lineman Lomas Brown, and Tight End Rob Rubick signed foam footballs, provided ...
(Date:7/29/2015)... Claremont, California (PRWEB) , ... July 29, 2015 , ... ... buy, sell, and trade goods and services may be able to unlock mysteries about ... Claremont Graduate University , Boston University, and Columbia University. , The findings, published ...
(Date:7/29/2015)... ... July 29, 2015 , ... The ... to crowd-funding campaigns that give small businesses financial support, social connections can be ... innovator in employee health management programs, unveiled today a downloadable resource for employers ...
Breaking Medicine News(10 mins):Health News:Elite Online Continuing Education Provider Adds Six New Athletic Training Courses to Exclusive Andrews Research and Education Sports Medicine Series 2Health News:Elite Online Continuing Education Provider Adds Six New Athletic Training Courses to Exclusive Andrews Research and Education Sports Medicine Series 3Health News:Three Important Product Liability Realities Offered In Light of News of Recent Product Recalls 2Health News:Three Important Product Liability Realities Offered In Light of News of Recent Product Recalls 3Health News:A Forever Recovery Holds Autograph Event with Former Detroit Lions at Cherry Festival 2Health News:University Researchers Apply Economic Concepts to Explore the Mysteries of the Microbial World 2Health News:University Researchers Apply Economic Concepts to Explore the Mysteries of the Microbial World 3Health News:StayWell Unveils Employer Guide to Developing Effective Employee Wellness Champion Networks 2Health News:StayWell Unveils Employer Guide to Developing Effective Employee Wellness Champion Networks 3Health News:StayWell Unveils Employer Guide to Developing Effective Employee Wellness Champion Networks 4
... ... Company, Inc. has launched a new website dedicated solely to its new ... of materials relating to ZaGO,s switchboot production capabilities including detailed information about ... its bonding, color matching and custom sealing solutions. Easy to use ...
... beneficial for many patients, unexpected consequences are emerging in ... reflux diseases. Physicians are warned to monitor these effects ... commentary published in the November 2009 issue of ... According to the authors, gastroesophageal reflux(GERD) and laryngopharyngeal reflux ...
... study in the Nov.1 issue of the journal ... to shift from a more automatic, implicit process of ... (rule-based). This use of rule-based strategies in a ... to potentially devastating errors when quick and accurate categorization ...
... According to the Institute of Medicine, more than ... a mismatch between patients, abilities to understand healthcare ... information in an understandable manner. In two recent ... that two groups those with limited English ...
... approach to managing the high rate of heart disease ... research being presented at the American Society of Nephrology,s ... CA. Patients with advanced kidney disease have high ... from heart disease. Oral activated charcoala product called AST-120has ...
... HARTFORD, Conn., Oct. 31 Lowell Weicker, Jr., former three-term ... Board of the Trust for America,s Health (TFAH), delivered an ... The following are excerpts from the speech: , "If we ... millions of people will continue to become ill, suffer needlessly, ...
Cached Medicine News:Health News:ZaGO Manufacturing Company unveils new Switchboots Website 2Health News:Commentary warns of unexpected consequences of proton pump inhibitor use in reflux disease 2Health News:Study shows that sleep deprivation can negatively affect information processing 2Health News:Study shows that sleep deprivation can negatively affect information processing 3Health News:Health information not communicated well to minority populations, MU researcher finds 2Health News:Health information not communicated well to minority populations, MU researcher finds 3Health News:Former Connecticut Governor Lowell Weicker, Jr. Delivers Address on Health Reform 2Health News:Former Connecticut Governor Lowell Weicker, Jr. Delivers Address on Health Reform 3
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... ELISA test for Clostridium difficile antigen that ... sensitivity. That means the laboratory can quickly, ... negatives - which can represent up to ... the organism - and be sure that ...
... Difficile Tox A/B II is a second-generation rapid ... A and B in fecal specimens. The test ... results detecting not only the more common toxin ... A-/B+. It's easy to perform, produces no indeterminates ...
... now offers the first and only ... and monitoring of bladder cancer patients. ... quantitative microplate enzyme immunoassay that detects ... the urine of patients with bladder ...
Medicine Products: